Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $9.4 million.

  • 4D Molecular Therapeutics' Other Non-Current Assets rose 22751.4% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 22751.4%. This contributed to the annual value of $4.3 million for FY2024, which is 52295.32% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Other Non-Current Assets of $9.4 million as of Q3 2025, which was up 22751.4% from $9.4 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Other Non-Current Assets high stood at $9.4 million for Q2 2025, and its period low was $602000.0 during Q1 2021.
  • Its 5-year average for Other Non-Current Assets is $2.4 million, with a median of $1.1 million in 2022.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Other Non-Current Assets plummeted by 3880.95% in 2024, and later surged by 81348.9% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Other Non-Current Assets stood at $602000.0 in 2021, then skyrocketed by 79.4% to $1.1 million in 2022, then tumbled by 36.67% to $684000.0 in 2023, then soared by 522.95% to $4.3 million in 2024, then soared by 120.14% to $9.4 million in 2025.
  • Its Other Non-Current Assets stands at $9.4 million for Q3 2025, versus $9.4 million for Q2 2025 and $7.0 million for Q1 2025.